The relationship of homocysteine and its redox forms with renal toxicity after high-dose methotrexate treatment in patients with leukemia or lymphoma
- 1Department of Pharmacy, The Second Hospital of Hebei Medical University
- 2School of Pharmacy, Hebei Medical University
- 3Department of Orthopedics, Hebei Medical University Third Hospital
Abstract
Background: High-dose methotrexate (HD-MTX) chemotherapy inhibits dihydrofolate reductase, leading to impaired homocysteine metabolism, elevated levels, and associated clinical adverse reactions. Currently, studies often monitor total homocysteine (tHcy) levels, but its toxic mechanism remains unclear.
Objectives: Given the association between HD-MTX toxicity and oxidative stress, this study aimed to analyze the correlations between tHcy and its redox forms with liver/kidney function indicators, and to evaluate their discriminatory ability for hepatic and renal toxicity.
Methods: A total of 310 blood samples were collected from 89 patients (38 adults, 51 children) with leukemia or lymphoma treated with HD-MTX. Concentrations of tHcy, free reduced homocysteine (Hcy), free oxidized homocysteine (HHcy, homocystine), and the ratio of Hcy concentration to HHcy concentration (Hcy/HHcy) were measured at 42, 72, and 96 h post-chemotherapy. Generalized estimating equations (GEE) were used to assess associations between tHcy-related redox forms and liver/kidney function indicators, and to compare concentration differences between toxicity and non-toxicity groups. Receiver operating characteristic (ROC) curve analysis was applied to evaluate the discriminatory ability of relevant indicators for HD-MTX-related toxicity.
Results: In pediatric patients, Hcy/HHcy was significantly negatively correlated with creatinine (CR) ( P < 0.028), and tHcy was significantly negatively correlated with alanine aminotransferase (ALT), total bilirubin (TB), and direct bilirubin (DB). No significant associations were observed in adult patients. Compared with the control group, the kidney injury group showed significant differences in Hcy and HHcy levels at 42 h ( P < 0.05), Hcy at 72 h, and HHcy at 96 h. No significant differences were observed in the liver injury group. HHcy, tHcy, and Hcy/HHcy at 42 h all demonstrated good discriminatory ability for kidney injury, with HHcy showing an AUC of 0.817 (95% CI: 0.702–0.932, P < 0.01). tHcy at 72 h and 96 h showed reverse discriminatory ability for liver and kidney injury.
Conclusion: Alterations in tHcy redox status after HD-MTX treatment, particularly changes in HHcy levels and the Hcy/HHcy, may be associated with renal function changes and may have potential value for identifying patients with HD-MTX-related nephrotoxicity.
Related
- Relationship between homocysteine levels and carotid plaque burden in patients with diabetes: the mediating role of inflammation
- The Proposed Vitamin D–Homocysteine Relationship in Cardiometabolic Health: A Narrative Review of Mechanisms, Evidence, and Research Phenotypes
- Pretreatment prediction of early severe treatment-related toxicity in older patients with lung adenocarcinoma: same-center temporal validation of a risk model
- P014 Tibial fractures in patients on methotrexate—think about methotrexate osteopathy
- Machine Learning Models to Predict Methotrexate Treatment Response in Rheumatoid Arthritis: A Scoping Review
BibTeX
@article{gao2026relationship,
title = {{The relationship of homocysteine and its redox forms with renal toxicity after high-dose methotrexate treatment in patients with leukemia or lymphoma}},
author = {Shuai-Shuai Gao and Chun-Ling Wu and Zheng-Yang Liu and Jin-Xuan Zheng and Hong-Yu Zhou and Jin-Yan Xie and Jia-Liang Guo and Wei-Chong Dong},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1972047},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1972047/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The relationship of homocysteine and its redox forms with renal toxicity after high-dose methotrexate treatment in patients with leukemia or lymphoma
AU - Shuai-Shuai Gao
AU - Chun-Ling Wu
AU - Zheng-Yang Liu
AU - Jin-Xuan Zheng
AU - Hong-Yu Zhou
AU - Jin-Yan Xie
AU - Jia-Liang Guo
AU - Wei-Chong Dong
PY - 2026
DA - 2026/10/20
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1972047
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1972047/full
AB - Background: High-dose methotrexate (HD-MTX) chemotherapy inhibits dihydrofolate reductase, leading to impaired homocysteine metabolism, elevated levels, and associated clinical adverse reactions. Currently, studies often monitor total homocysteine (tHcy) levels, but its toxic mechanism remains unclear. Objectives: Given the association between HD-MTX toxicity and oxidative stress, this study aimed to analyze the correlations between tHcy and its redox forms with liver/kidney function indicators, and to evaluate their discriminatory ability for hepatic and renal toxicity. Methods: A total of 310 blood samples were collected from 89 patients (38 adults, 51 children) with leukemia or lymphoma treated with HD-MTX. Concentrations of tHcy, free reduced homocysteine (Hcy), free oxidized homocysteine (HHcy, homocystine), and the ratio of Hcy concentration to HHcy concentration (Hcy/HHcy) were measured at 42, 72, and 96 h post-chemotherapy. Generalized estimating equations (GEE) were used to assess associations between tHcy-related redox forms and liver/kidney function indicators, and to compare concentration differences between toxicity and non-toxicity groups. Receiver operating characteristic (ROC) curve analysis was applied to evaluate the discriminatory ability of relevant indicators for HD-MTX-related toxicity. Results: In pediatric patients, Hcy/HHcy was significantly negatively correlated with creatinine (CR) ( P < 0.028), and tHcy was significantly negatively correlated with alanine aminotransferase (ALT), total bilirubin (TB), and direct bilirubin (DB). No significant associations were observed in adult patients. Compared with the control group, the kidney injury group showed significant differences in Hcy and HHcy levels at 42 h ( P < 0.05), Hcy at 72 h, and HHcy at 96 h. No significant differences were observed in the liver injury group. HHcy, tHcy, and Hcy/HHcy at 42 h all demonstrated good discriminatory ability for kidney injury, with HHcy showing an AUC of 0.817 (95% CI: 0.702–0.932, P < 0.01). tHcy at 72 h and 96 h showed reverse discriminatory ability for liver and kidney injury. Conclusion: Alterations in tHcy redox status after HD-MTX treatment, particularly changes in HHcy levels and the Hcy/HHcy, may be associated with renal function changes and may have potential value for identifying patients with HD-MTX-related nephrotoxicity.
SN - 1663-9812
ER -